Show simple item record

dc.contributor.authorBadiyan, S.
dc.contributor.authorKaiser, A.
dc.contributor.authorEastman, B.
dc.date.accessioned2020-06-01T18:26:16Z
dc.date.available2020-06-01T18:26:16Z
dc.date.issued2020
dc.identifier.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85085139943&doi=10.21037%2fTGH.2019.10.07&partnerID=40&md5=f60658dc90f5a710b3f404dad0a64383
dc.identifier.urihttp://hdl.handle.net/10713/12914
dc.description.abstractImmunotherapy represents the newest pillar in cancer care. Although there are increasing data showing the efficacy of immunotherapy there is a spectrum of response across unselected populations of cancer patients. In fact, response rates can be poor even among patients with immunogenic tumors for reasons that remain poorly understood. A promising clinical strategy to improve outcomes, which is supported by an abundance of preclinical data, is combining immunotherapy with radiation therapy. Here we review the existing evidence and future directions for combining immunotherapy and radiation therapy for patients with gastrointestinal cancers.en_US
dc.description.urihttps://doi.org/10.21037/TGH.2019.10.07en_US
dc.language.isoen_USen_US
dc.publisherAME Publishing Companyen_US
dc.relation.ispartofTranslational Gastroenterology and Hepatology
dc.subjectCanceren_US
dc.subjectImmunotherapyen_US
dc.subjectRadiation therapyen_US
dc.titleImmunotherapy and radiation therapy for gastrointestinal malignancies: Hope or hype?en_US
dc.typeArticleen_US
dc.identifier.doi10.21037/TGH.2019.10.07


This item appears in the following Collection(s)

Show simple item record